Clinical trials: Oligoprogression
Early Stage Non-Small Cell Lung Cancer
Safety Trial of Antimicrobial Therapy and Precision Radiation Therapy in Patients With Oligoprogressive Non-small Cell Lung Cancer
The first phase of this study was an open label, randomized pilot study. Enrollment for this phase is now complete. The second phase is a single arm phase 1 safety study.
- Trial name
- NCT03546829
- Testing
- Vancomycin, Precision hypofractionated radiation
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
HCC - Hepatocellular Carcinoma, Radiotherapy
Efficacy and Safety of Radiotherapy in Oligoprogressive HCC Following First-line PD-1 Therapy
Immune checkpoint inhibitors (ICIs) have significantly improved the survival outcomes of HCC patients. However, a considerable proportion of patients eventually experience disease progression due to the development of resistance.
- Trial name
- NCT06870942
- Testing
- Maintenance first-line treatment plus radiation therapy
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Shanghai Zhongshan Hospital
Metastatic Cancer, Oligoprogressive
Stereotactic Ablative Radiotherapy for Oligo-Progressive Disease REfractory to Systemic Therapy in Metastatic Cancer
A registry-based randomized phase II trial. A total of 46 patients with metastatic cancer on systemic therapy with oligoprogression to 1-5 extracranial lesions will be randomized using a 1:1 ratio to standard of care (begin…
- Trial name
- SUPPRESS (NCT04989725)
- Testing
- Standard arm, Experimental arm
- Where
- Canada
- Volunteers
- 46 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Non-small Cell Lung Cancer, Oligoprogressive
LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE)
This is a phase 2 pragmatic study that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary objective.
- Conditions
- Non-small Cell Lung Cancer, Oligoprogressive, Small-cell Lung Cancer
- Trial name
- OBLITERATE (NCT06103682)
- Testing
- Ablative local therapy
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of California, Davis
Oligoprogressive
Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies
Phase 2, open-label, multicenter, randomized study comparing the safety and efficacy of personalized ultra-fractionated stereotactic adaptive radiotherapy (PULSAR) combined with immune checkpoint inhibitor (ICI) immunotherapy…
- Trial name
- NCT05846659
- Testing
- IMSA101, Immune checkpoint inhibitor, PULSAR
- Where
- 14 sites in United States
- Volunteers
- 16 people
- Sponsor
- ImmuneSensor Therapeutics Inc.
Oligoprogressive, Castration-Resistant Prostate Cancer
Stereotactic Ablative Radiation Therapy for Abiraterone-Resistant, Oligoprogressive Metastatic Prostate Cancer
There is increasing worldwide interest in exploring stereotactic ablative body radiotherapy (SABR) for treating metastases in men with prostate cancer, including for the treatment of oligoprogressive metastases.
- Trial name
- NCT04838899
- Testing
- Stereotactic Body Radiation Therapy (SABR)
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Sunnybrook Health Sciences Centre
Metastatic Prostate Cancer, Castration-resistant Prostate Cancer
Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)
This is the first pilot phase II trial assessing the response of SBRT layered on Darolutamide (BAY1841788) on RPFS and deferring palliative second line systemic therapy in M0CRPC with oligoprogression.
- Trial name
- NCT04070209
- Testing
- Darolutamide (BAY1841788), SBRT
- Where
- 11 sites in Canada
- Volunteers
- 66 people
- Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma
This Phase II trial will evaluate progression-free survival after Stereotactic Body Radiation Therapy to oligoprogressive (1-5) lesions in metastatic renal cell carcinoma patients on any immune checkpoint inhibitor-containing…
- Conditions
- Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Oligoprogressive, Progression
- Trial name
- NCT04974671
- Testing
- Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Yale University
Castration-resistant Prostate Cancer, Oligoprogressive
Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer
Evaluation of the impact of metastasis-directed therapy in patients with castration-refractory prostate cancer and a maximum of 5 progressive lesions.
- Trial name
- MEDCARE (NCT06585007)
- Testing
- Radiotherapy, metastasectomy
- Where
- Belgium
- Volunteers
- 246 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Metastatic Renal Cell Carcinoma, Radiotherapy
A Phase II Study Assessing Stereotactic Radiotherapy in Therapeutic Strategy of Oligoprogressive Renal Cell Carcinoma Metastases
Every year, 12500 primary renal cell carcinoma (RCC) are diagnosed in France. Metastases occur in half of RCC patients. Management of metastatic RCC is based on systemic treatments (targeted therapies/immunotherapy).
- Trial name
- GETUG-StORM-01 (NCT04299646)
- Testing
- Steretactic radiotherapy
- Where
- 30 sites in France
- Volunteers
- 77 people
- Sponsor
- Centre Francois Baclesse
Hepatocellular Carcinoma, Oligoprogression
Second-line Systemic Therapy Combined with SBRT for HCC with Oligoprogression After Standard First-line Systemic Treatment
Approximately 70% of hepatocellular carcinoma (HCC) patients are diagnosed at an advanced stage, with no opportunity for curative treatments. For these patients, systemic therapies are the main treatment modalities.
- Trial name
- NCT06592612
- Testing
- SBRT and second-line systemic therapy, Second-line systemic therapy
- Volunteers
- 70 people
- Sponsor
- Sun Yat-sen University
Non Small Cell Lung Cancer, Oligoprogressive
Local Consolidative Radiotherapy for Oligoprogressive in Non-small Cell Lung Carcinoma
This is a randomized phase II study designed to evaluate the effect of local consolidative radiation therapy (LCT) to all sites of oligoprogressive disease in patients with metastatic non-small cell lung carcinoma who have…
- Trial name
- NCT04485026
- Testing
- Local consolidative radiation therapy, Standard of care radiation therapy
- Sponsor
- Wake Forest University Health Sciences
Castrate Resistance Prostate Cancer, OligoProgressive Metastatic Disease
Stereotactic Body Radiotherapy or Standard of Care for Prostate Oligoprogressive Cancer
This is a single centre, interventional, randomized Phase II, two-arm prospective trial investigating if Stereotactic Body Radiotherapy (SBRT) to all sites of Oligopressive (OP) disease while remaining on current Systemic Therapy…
- Trial name
- SECURE (NCT06927635)
- Testing
- Stereotactic Body Radiation Therapy (SBRT), Systemic therapy
- Where
- Canada
- Volunteers
- 75 people
- Sponsor
- University Health Network, Toronto
Non-small Cell Lung Cancer, Oligoprogressive
A Study of Furmonertinib Combined With Radiotherapy for Non-small Cell Lung Cancer With Oligoprogression
This Phase II randomized study is to explore the efficacy and safety of Furmonertinib combined with radiotherapy for non-small cell lung cancer with oligoprogression after first-line EGFR-TKI therapy.
- Trial name
- NCT04970693
- Testing
- Furmonertinib
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Sun Yat-sen University
Metastatic Breast Cancer, Oligoprogression
STereotactic Body Radiotherapy (SBRT) for Oligoprogressive Breast Cancer
Recent advances in systemic therapy have facilitated improved progression-free survival (PFS) and treatment tolerability in metastatic breast cancer patients (MBC).
- Trial name
- STAR-B (NCT06489821)
- Testing
- Stereotactic body radiotherapy
- Volunteers
- 36 people
- Sponsor
- Juravinski Cancer Center
Brain Metastasis, Oligoprogression
Stereotactic Radiotherapy in Oligometastatic Brain Disease: a Randomised Phase III Study Comparing Hypofractionated Stereotactic Radiation Therapy (3*10 Gy) to the Historical Single-dose Radiosurgery (1*20 to 25 Gy) With Medico-economic Evaluation.
Brain metastases (BM) are a common systemic cancer manifestation which incidence increases. Therapeutic options include whole-brain radiotherapy (WBRT), surgery, and stereotactic radiosurgery (SRS).
- Trial name
- OligoBM-01 (NCT05102747)
- Testing
- Hypofractionated SRT (stereotactic radiotherapy), Historical single-dose SRS (stereotactic radiosurgery)
- Where
- 15 sites in France
- Volunteers
- 504 people
- Sponsor
- Centre Francois Baclesse
Cervical Cancer, Gynecologic Cancer
Radiotherapy for Gynecologic Cancer With Up to 10 Active Metastatic Lesions
OLIGYNE-10 RT is an international registry of adults with gynecologic cancer and a limited number of active sites of cancer spread who receive radiotherapy (RT) to at least one metastatic lesion during routine care.
- Conditions
- Cervical Cancer, Gynecologic Cancer, Endometrial Cancer, Uterine Cancer
- Trial name
- OLIGYNE-10 RT (NCT07883798)
- Testing
- Routine-care metastasis-directed radiotherapy
- Where
- Poland
- Volunteers
- 500 people
- Sponsor
- Affidea Nu-med Center of Oncological DIagnostics and Therapy
Metastatic Renal Cell Carcinoma ( mRCC), OligoProgressive Metastatic Disease
Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer
To evaluate the impact of combining innate immune system activation (with IMSA101) with antigen release (through SAbR/PULSAR) on limited progressing lesions during ongoing adaptive immune system activation (with maintenance Nivo).
- Trial name
- SPARK (NCT06601296)
- Testing
- IMSA101
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Texas Southwestern Medical Center
NSCLC Stage IV
Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC
Multicentre, phase II, open-label, single-arm study evaluating the preliminary efficacy, safety and tolerability of atezolizumab in association with palliative radiotherapy in adult patients diagnosed with advanced (stage IV)…
- Trial name
- NCT04549428
- Testing
- Atezolizumab
- Where
- 3 sites in Switzerland
- Volunteers
- 12 people
- Sponsor
- Oncology Institute of Southern Switzerland
Pancreas Cancer, Lung Cancer
Stereotactic Magnetic Resonance Guided Radiation Therapy
This is a master prospective Phase I-II trial evaluating feasibility and efficacy of stereotactic magnetic resonance (MR) guided adaptive radiation therapy (SMART) in patients with cancer.
- Conditions
- Pancreas Cancer, Lung Cancer, Renal Cancer, Adrenal Metastases
- Trial name
- NCT04115254
- Testing
- MR-guided Linac
- Where
- 2 sites in United States
- Volunteers
- 397 people
- Sponsor
- Dana-Farber Cancer Institute